Outlook Therapeutics (OTLK) Competitors $1.84 -0.06 (-3.16%) Closing price 04:00 PM EasternExtended Trading$1.90 +0.06 (+3.26%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. AARD, TVRD, LFCR, ZYBT, ESPR, DBVT, MDWD, YMAB, TIL, and SLRNShould you be buying Outlook Therapeutics stock or one of its competitors? The main competitors of Outlook Therapeutics include Aardvark Therapeutics (AARD), Cara Therapeutics (TVRD), Lifecore Biomedical (LFCR), Zhengye Biotechnology (ZYBT), Esperion Therapeutics (ESPR), DBV Technologies (DBVT), MediWound (MDWD), Y-mAbs Therapeutics (YMAB), Instil Bio (TIL), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry. Outlook Therapeutics vs. Aardvark Therapeutics Cara Therapeutics Lifecore Biomedical Zhengye Biotechnology Esperion Therapeutics DBV Technologies MediWound Y-mAbs Therapeutics Instil Bio Acelyrin Outlook Therapeutics (NASDAQ:OTLK) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations. Is OTLK or AARD more profitable? Company Net Margins Return on Equity Return on Assets Outlook TherapeuticsN/A N/A -225.12% Aardvark Therapeutics N/A N/A N/A Does the media refer more to OTLK or AARD? In the previous week, Outlook Therapeutics had 3 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 7 mentions for Outlook Therapeutics and 4 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.50 beat Outlook Therapeutics' score of 0.18 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Outlook Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in OTLK or AARD? 11.2% of Outlook Therapeutics shares are held by institutional investors. 4.8% of Outlook Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, OTLK or AARD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOutlook TherapeuticsN/AN/A-$75.37M-$0.91-2.02Aardvark TherapeuticsN/AN/AN/AN/AN/A Do analysts recommend OTLK or AARD? Outlook Therapeutics currently has a consensus target price of $9.60, suggesting a potential upside of 421.74%. Aardvark Therapeutics has a consensus target price of $31.25, suggesting a potential upside of 165.51%. Given Outlook Therapeutics' higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor OTLK or AARD? Outlook Therapeutics received 159 more outperform votes than Aardvark Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Aardvark Therapeutics an outperform vote while only 70.76% of users gave Outlook Therapeutics an outperform vote. CompanyUnderperformOutperformOutlook TherapeuticsOutperform Votes16770.76% Underperform Votes6929.24% Aardvark TherapeuticsOutperform Votes880.00% Underperform Votes220.00% SummaryOutlook Therapeutics beats Aardvark Therapeutics on 5 of the 9 factors compared between the two stocks. Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOutlook TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.77M$3.10B$5.57B$8.66BDividend YieldN/A1.59%5.27%4.19%P/E Ratio-0.2533.8227.2020.17Price / SalesN/A476.37412.92161.90Price / CashN/A168.6838.2534.64Price / Book-1.173.497.114.72Net Income-$75.37M-$72.35M$3.23B$247.80M7 Day Performance-0.54%10.49%4.61%3.36%1 Month Performance19.87%24.23%13.35%9.71%1 Year Performance-73.97%-15.55%31.75%14.41% Outlook Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOutlook Therapeutics1.8373 of 5 stars$1.84-3.2%$9.60+421.7%-72.0%$61.77MN/A-0.2520Gap UpAARDAardvark TherapeuticsN/A$11.68-1.1%$31.25+167.6%N/A$253.41MN/A0.0018Analyst RevisionGap UpTVRDCara TherapeuticsN/A$26.90-5.6%$65.00+141.6%N/A$251.81MN/A0.0080Gap UpHigh Trading VolumeLFCRLifecore Biomedical1.6378 of 5 stars$6.78-1.0%$8.00+18.0%+14.7%$251.03M$130.31M-12.11690ZYBTZhengye BiotechnologyN/A$5.16-12.7%N/AN/A$243.38M$189.75M0.00278Gap UpESPREsperion Therapeutics4.1769 of 5 stars$1.20-1.6%$6.25+420.8%-57.1%$237.84M$259.57M-1.88200Options VolumeDBVTDBV Technologies3.0938 of 5 stars$8.68-4.9%$14.75+69.9%+71.9%$237.75M$15.73M-1.9380Gap DownMDWDMediWound1.9564 of 5 stars$21.46-0.6%$31.80+48.2%+25.9%$231.94M$19.21M-7.4080YMABY-mAbs Therapeutics3.4456 of 5 stars$5.08-3.6%$15.60+207.1%-57.6%$230.04M$88.66M-9.41150Analyst RevisionTILInstil Bio3.2687 of 5 stars$35.07+6.6%$119.00+239.3%+227.8%$230.02MN/A-3.03410Gap UpHigh Trading VolumeSLRNAcelyrin2.9436 of 5 stars$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135Positive News Related Companies and Tools Related Companies Aardvark Therapeutics Competitors Cara Therapeutics Competitors Lifecore Biomedical Competitors Zhengye Biotechnology Competitors Esperion Therapeutics Competitors DBV Technologies Competitors MediWound Competitors Y-mAbs Therapeutics Competitors Instil Bio Competitors Acelyrin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OTLK Stock Free OTLK Stock Alerts